Last reviewed · How we verify
Saxagliptin, Onglyza
Saxagliptin, Onglyza is a DPP-4 inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: Onglyza.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Saxagliptin, Onglyza |
|---|---|
| Also known as | Onglyza |
| Sponsor | AstraZeneca |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By blocking DPP-4, saxagliptin prevents the degradation of GLP-1 and GIP, incretin hormones that stimulate glucose-dependent insulin release and suppress glucagon secretion. This mechanism lowers postprandial and fasting blood glucose levels in patients with type 2 diabetes without causing hypoglycemia when used as monotherapy, since insulin secretion is glucose-dependent.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Urinary tract infection
- Headache
- Upper respiratory tract infection
- Hypoglycemia (when combined with other agents)
Key clinical trials
- Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
- Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
- SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saxagliptin, Onglyza CI brief — competitive landscape report
- Saxagliptin, Onglyza updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Saxagliptin, Onglyza
What is Saxagliptin, Onglyza?
How does Saxagliptin, Onglyza work?
What is Saxagliptin, Onglyza used for?
Who makes Saxagliptin, Onglyza?
Is Saxagliptin, Onglyza also known as anything else?
What drug class is Saxagliptin, Onglyza in?
What development phase is Saxagliptin, Onglyza in?
What are the side effects of Saxagliptin, Onglyza?
What does Saxagliptin, Onglyza target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4 (dipeptidyl peptidase-4)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Onglyza
- Compare: Saxagliptin, Onglyza vs similar drugs
- Pricing: Saxagliptin, Onglyza cost, discount & access